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ABSTRACT 
 
Investigating The Role Of Zoledronic Acid On Interleukin-6 Cytokine 
Expression In Prostate Cancer Cell Lines 
 
Prostate cancer (CaP) is a common disease in aged men. Androgen deprivation 
therapy is the first line treatment for advanced disease. Following this therapy, within 
few months CaP cells become androgen independent in a few mounths. The mechanism 
responsible for development of androgen-independent cancer is not known. Evidences 
suggest that growth factors and cytokines including Interleukin–6 (IL-6) cast a main 
role in this mechanism. IL–6 is an important cytokine on CaP progression. 
Bisphosphonates inhibit the proliferation and induce the apoptosis of certain prostate 
cancer cell lines, in vitro.  However, their mechanism of action is not clearly 
understood.  One possible mechanism might be the IL-6 mediated pathway. This 
relation between zoledronic acid (ZA) and IL-6 hasn’t been studied. 
The objective of this study is to evaluate the cytotoxic and apoptotic effect of 
ZA on hormone independent CaP cell line (PC-3) and to understand the relation of 
underlying mechanism of ZA-mediated cytotoxicity and IL-6 expression.  
PC-3 cells were treated with different concentrations of ZA. Drug-mediated 
cytotoxicity and apoptosis were determined. IL-6 levels were measured from the 
supernatants of PC-3 cells at 24, 48, 72 hrs. 
Maximum cytotoxicity was achieved at 90 and 100 µM of ZA. ZA produced 
the classical DNA ladders on gel synonymous of apoptosis. The decrease in IL-6 
secretion was found to be statistically significant compared to controls. The decreasing 
effect of ZA on IL-6 expression might suggest a new mechanism of action of ZA’s 
antitumor activity. This outcome may offer a novel therapy that utilizes IL-6 antagonists 
along with ZA in CaP patients. 
 v 
ÖZET 
 
PROSTAT KANSER HÜCRE HATLARINDA ZOLEDRONK ASDN 
NTERLÖKN-6 STOKNNN EKSPRESYONU ÜZERNDEK 
ROLÜNÜN ARATIRILMASI 
 
Prostat kanseri günümüzde ileri ya erkekler arasında en sık görülen kanser 
tipidir. Hastalıın ileri evresinde kullanılan tedavi androjen baskılanmasıdır. Androjen 
baskılanmasından kısa bir süre sonra prostat kanseri hücrelerinin birçou hormondan 
baımsız çoalmaya devam ederler. Bu çoalmanın mekanizması henüz bilinmemekle 
birlikte çeitli büyüme faktörleri ve sitokinlerin bu mekanizmada önemli rol aldıı 
düünülmektedir. nterlökin–6 (IL–6) prostat kanserinin ilerlemesinde önemli bir 
sitokindir. Bifosfonatlar, çeitli prostat kanser hücre hatlarında çoalmayı önleyici ve 
apoptozisi tetikleyici bir etki göstermektedir, fakat etki mekanizmaları henüz 
bilinmemektedir. Olası mekanizmalardan biri IL–6 yolaı üzerinden olabilir. u ana 
kadar Zoledronik asit (ZA) ile IL–6 ilikisini ortaya koyan bir çalıma yapılmamıtır. 
Bu çalımanın amacı, hormon-dirençli prostat kanseri hücre hattı (PC–3) 
üzerinde ZA’nın sitotoksik ve apoptotik etkisini göstererek ilaca balı meydana gelen 
bu sitotoksisitenin mekanizmasının IL–6 ile ilikisini saptamaktır. 
PC–3 hücreleri farklı konsantrasyonlarda ZA ile inkübe ediltikten sonra 
ZA’nın PC–3 hücreleri üzerindeki sitotoksisitesi ve apoptotik etkisi ölçüldü.  Hücrelerin 
süpernatantlarındaki IL–6 düzeyleri 24, 48 ve 72 saatlerde ölçüldü.  
Maksimum sitotoksisiteye ZA’nın 90 ve 100 µM konsantrasyonunda ulaıldı.  
ZA ile inkübasyon sonrasında apoptozisin göstergesi olan DNA merdiven oluumu jel 
üzerinde gözlendi.  Kontrol grubuna oranla IL–6 salınımındaki azalmalar istatistiksel 
açıdan anlamlı bulundu. ZA’nın IL–6 ekspresyonu üzerindeki azaltıcı etkisi, ZA’nın 
antitümör aktivitesinde yeni bir mekanizmanın varlıına iaret etmektedir.  Bu sonuç, 
prostat kanserli hastalarda zoledronik asitle birlikte IL–6 antagonistlerinin kullanılması 
ile yeni bir tedavi seçeneine kapı açmaktadır. 
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CHAPTER 1 
 
INTRODUCTION 
 
 Our growing understanding of cancer cell biology should lead to better ways of 
diagnosis and treating this disease. Anticancer therapies can be designed to destroy 
cancer cells preferentially by exploiting the properties that distinguish them from 
normal cells, including the defects they harbor in their DNA repair mechanisms, cell 
cycle check points, and apoptosis pathways. Tumors can also be attacked through their 
dependence on their blood supply. By understanding the normal control mechanisms 
and how they are subverted in specific cancers, it becomes possible to devise drugs to 
target cancers more precisely. Cancer cells are defined by two heritable properties: they 
and their progeny reproduce in defiance of the normal restraints on cell division and 
invade and colonize territories normally reserved for other cells. It is the combination of 
these actions that makes cancer dangerous. An isolated abnormal cell that does not 
proliferate more than its neighbors does no significant damage, no matter what other 
disagreeable properties it may have; but if its proliferation is out of control, it will give 
rise to a tumor, or neoplasm- a growing mass of abnormal cells. As long as the 
neoplastic cells remain clustered together in a single mass, the tumor is said to be 
benign. At this stage, a complete cure can usually be achieved by removing the mass 
surgically. A tumor is considered a cancer only if it is malignant, that is, only if its cells 
have acquired the ability to invade surrounding tissue. Invasiveness usually implies an 
ability to break loose, enter the bloodstream or lymphatic vessels, and form secondary 
tumors, called metastases, at other sites in the body. The more widely a cancer spreads, 
the harder it becomes to eradicate. 
Prostate cancer is a common disease in aged men. Normal and early stage 
prostate cancer cells require androgen for growth and survival, which led to the 
formulation and successful application of androgen ablation and anti-androgen therapies 
as principal treatment modalities for the disease. However, beneficial effects of the 
hormonal therapies are often temporary, and the cancer regularly progresses to the 
androgen-refractory stage characterized by recurrent growth and metastasis, 
predominantly to bone (Feldman et al, 2001, Nelson et al, 2003). Despite decades of 
 2 
intense laboratory and clinical research, to date there is no cure for androgen-refractory 
prostate cancer. The existence of androgen-independent prostate tumors suggests that 
release of locally produced and/or circulating growth factors such as Interleukin-6, 
which work through cellular receptors, can switch the prostate cells from an inactive to 
an activated phenotype leading to cellular proliferation. The majority of prostate cancers 
arise from epithelial cells, and in tissue cultures, epithelial prostate cancer cells produce 
factors that act in an autocrine fashion to regulate their growth and survival (Xie et al, 
2002, Berger et al, 2003). 
Interleukin-6 (IL-6) is a multifunctional cytokine which is involved in regulation 
of growth of various malignant tumors. IL-6 also regulates gene expression in a number 
of different organs, modulates immune function, stimulates the hypothalamic-pituitary 
axis, promotes osteoclasting resorption in bone, and stimulates bone marrow (Ershler et 
al, 2000). The biological activities of IL-6 are mediated by the IL-6 receptor, which 
binds IL-6 specifically and with low affinity, and gp130, which associates with the IL-
6-IL-6 receptor complex, resulting in high-affinity binding and activation of 
intracellular signaling. The evidences were shown that IL-6 may be an important 
autocrine and/or paracrine growth factor for prostate cancer and may contribute to 
cancer progression (Siegall et al, 1990, Okamoto et al, 1997, Siegsmund MJ et al, 1994, 
Hobisch A et al, 2000). For example, inhibition of IL-6, with anti-IL-6 antibody, 
sensitizes androgen-independent prostate cancer cells to chemotherapeutic agents in 
vitro.  Additionally, IL-6 induces androgen receptor (AR) activity through both 
increasing AR gene expression and activating the AR in the absence of androgen in 
prostate cancer cells (Lin et al, 2001). These data suggest that targeting IL-6 may have 
multiple benefits in prostate cancer patients. 
Bisphosphonates inhibits the proliferation and induces the apoptosis of certain 
prostate cancer cell lines, in vitro (Lee et al, 2001). Zoledronic acid, nitrogen-containing 
bisphosphonate, is used in prostate cancer patients according to laboratory evidence 
documenting that prostate cancer bone metastases are associated with an increased 
osteoclast-mediated bone resorption (Ikeda et al, 1996, Maeda et al, 1997). Furthermore, 
preclinical studies suggest that bisphosphonates possess antitumor activity and can 
inhibit proliferation and induce apoptosis of tumor cell lines (Lipton et al, 2004).   
In this study, we discuss prostate cancer as a model and try to find out drug-
mediated cytotoxicity of zoledronic acid on hormone independent prostate cancer cell 
line and its mechanism of action. Thus, we first considered more closely what prostate 
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cancer is and its current treatments. Then we reviewed zoledronic acid and its role in 
prostate cancer treatment. Finally, we examined the function of interleukin-6 in prostate 
cancer cells. The objective of the study is to confirm the known apoptotic and cytotoxic 
effect of zoledronic acid in PC–3 prostate cell line and investigate the role of zoledronic 
acid on the expression of IL–6 in this cell line.  
  
1.1 Prostate Cancer and Treatment 
 
Prostate cancer is the fourth most common cancer in men, worldwide, with 
incidence and mortality rates that vary markedly among and within different countries. 
Since the early 1990s, new screening tests and improved treatments have been 
associated with dramatic shifts in the incidence, stage at diagnosis, and mortality of this 
disease. Major advances in molecular biology and epidemiology have provided new 
insights into the etiology and biology of prostate cancer. These developments promise 
to transform our understanding of this disease and will likely lead to new and better 
ways to prevent and treat prostate cancer in the future.Incidence and mortality rates vary 
tremendously among countries. Incidence and mortality rates are generally higher in 
Western countries than in developing countries. There are multiple complex causes for 
the worldwide and ethnic variations in prostate cancer incidence. The two major factors 
are genetics and environment. Prostate cancer is predominantly a disease of the elderly 
man, with more than 75% of new prostate cancers being diagnosed in men older than 65 
years. The incidence of prostate cancer in men age 50 to 59 years, however, has 
increased substantially since the 1970s. 
Although the specific causes of prostate cancer initiation and progression are not 
yet known, considerable evidence suggests that both genetics and environment play a 
role in the evolution of this disease. Classic and molecular epidemiology studies have 
identified a number of potential risk factors associated with the development of prostate 
cancer. A number of case-control studies have demonstrated familial clustering of 
prostate cancer, suggesting that some prostate cancers may be inherited. The clinical 
characteristics of familial prostate cancers have also been characterized to determine if 
hereditary prostate cancer may be more aggressive. 
Prostate cancer initiation and progression are influenced by androgens. Prostate 
tumors are exquisitely sensitive to androgens and regress after medical or surgical 
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castration. Ross and colleagues hypothesized that the higher incidence of prostate 
cancer observed in African Americans may be related to elevated levels of circulating 
androgen (Ross et al, 1998).  
Although the exact etiology of prostate cancer remains unknown, there has been 
tremendous progress in defining the molecular events responsible for the initiation and 
progression of this disease. This progress has resulted from a number of factors. 
Increased funding for prostate cancer research has focused and accelerated efforts in the 
field. Prostate cancers develop from the accumulation of genetic alterations that result in 
an increase in cell proliferation relative to cell death, arrest differentiation, and confer 
the ability to invade, metastasize, and proliferate in a distant site. Histologic changes are 
present in the prostates of men in their 20s, yet the diagnosis is typically made 3 to 4 
decades later, which suggests that the development of the disease is a multistep process 
(Sakr et al, 1993). The alterations include somatic point mutations, gene deletions, 
amplifications, chromosomal rearrangements, and changes in DNA methylation (Nelson 
et al, 2003). It is believed that the accumulation of changes acting synergistically is 
more critical than the order in which the alterations occur. Identifying and 
understanding the events has implications for control of the disease at the earliest stages 
of transformation, for progression as an invasive tumor, for prognostication, and for 
points of therapeutic attack. Men who are castrated before the age of 40 years rarely 
develop prostate cancer (Montie et al, 1994). The evolution of the tumor is influenced 
by hormonal factors; it is also influenced by environmental, infectious/inflammatory 
factors, and, given the long history once the diagnosis is established, the specific 
therapy (ies) used to treat the disease. The alterations include a reduction in defense 
against carcinogen-induced damage, inflammation, and changes in androgen signaling 
and changes in growth-regulatory genes that contribute to cell proliferation, survival, 
and spread.  
Neoplastic growth is the result of genetic, hormonal, environmental, and 
possibly infectious factors that modulate the expression of specific genes. The normal 
mutation frequency of DNA (1 x 10–10) is too low to produce significant changes in 
overall gene expression. It is now believed that tumor cells themselves have an inherent 
genetic instability that results in the coexistence of multiple genetically related, yet 
distinct, clones within a tumor mass (Sarasin et al, 2003). Clones with a survival 
advantage continue to proliferate, whereas those that acquire changes that reduce 
viability undergo cell death.  
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Overexpression of certain growth factors, such as epidermal growth factor 
(EGF), basic fibroblast growth factor, and platelet-derived growth factor (PDGF), has 
been reported to be involved in prostate cancer as autocrine and paracrine signaling 
loops together with their corresponding receptors (EGFR, fibroblast growth factor 
receptor, and IL–6) (Scher et al, 1995, Uehara et al, 2003, Culig et al, 1996). The 
insulin-like growth factor–1 and -2 (IGF–1, IGF–2), and transforming growth factor-  
and -  (TGF- , TGF- ) and their receptors (IGFR and TGFR, respectively) have also 
been implicated (Cardillo et al, 2003, Tu et al, 2003). IGFs are potent mitogens for 
human prostate cancer cells and osteoblasts via interaction with IGF receptors. Elevated 
levels of serum IGF-binding proteins have been reported in metastatic human prostate 
cancer. HER–2/neu protein is a transmembrane tyrosine kinase receptor with strong 
homology to EGFR. Amplification of the HER–2/neu gene and overexpression of the 
protein have prognostic significance in breast cancer and are used to select therapy. 
HER–2/neu amplification in prostate cancer is uncommon. Nevertheless, increased 
HER2/neu protein was found in 20% of untreated hormone-naive primary tumors, 
whereas overexpression was observed in 80% of metastatic cases and more than 60% of 
primary tumors surviving after androgen ablation. Investigators have also reported 
HER2 can activate AR independent of ligand (Craft et al, 1999).  
The major cause of death from prostate cancer is progressive castration-resistant 
disease, a tumor that continues to grow despite castrate levels of testosterone. As 
prostate cancers evolve to castration resistance, PSA synthesis resumes. The current 
view is that prostatic cancers at the time of diagnosis are composed of cells with three 
distinct cellular phenotypes: androgen-dependent, androgen-sensitive, and androgen-
independent cells. Androgen-dependent cancer cells continuously require a critical level 
of androgenic stimulation for maintenance and growth (i.e. without adequate androgenic 
stimulation, these cells die) and, in this regard, are very similar to the androgen-
dependent non-neoplastic cells of the normal prostate. The growth of androgen-sensitive 
cancer cells slows when androgens are withdrawn and they become dormant. They do 
not die. In contrast, the growth of androgen-independent cells does not change after 
androgen deprivation, no matter how complete; these cells are completely free of 
androgenic effects on growth (Arnold et al, 2002, Isaacs et al, 1992). In contrast to what 
can be accomplished in vitro using charcoal-stripped serum to eliminate androgens 
completely, in vivo it is virtually impossible to eliminate all androgens completely.  
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How do resistant tumor cells emerge during androgen ablation therapy? Some 
researchers theorize that selection of resistant cells occurs, whereas others suggest that, 
under the pressure of androgen-ablative therapies, cells that were sensitive only to the 
point at which growth was slowed without cell death adapt to the low androgen 
environment and, over time, acquire additional somatic changes that result in tumor 
regrowth (Isaacs et al, 1981, Craft et al, 1999, Bruchovsky et al, 1990). Clinically, 
selection of resistant or insensitive cells may be more relevant immediately after 
androgen withdrawal and adaptation more important later. The observation that basal 
epithelial cells preferentially survive androgen ablation (in contrast to secretory 
epithelial cells) demonstrates that intrinsically resistant cells do exist even in the normal 
prostate gland, in line with the selection hypothesis. This is consistent with the theorized 
role of basal cells as the stem cells for the prostatic epithelium (De Marzo et al, 1998, 
Bui et al, 1998, Isaacs et al, 1999). Unknown is whether the first transformed cell that 
ultimately develops into the self-renewing stem cell of a prostate cancer is dependent, 
sensitive, or insensitive to androgens. It is also difficult to determine whether the 
resistant/surviving cell population has a more basal or stem cell genotype, or a basal or 
a more differentiated cell that has been transformed. That hormonal ablation alone 
cannot eradicate the disease completely in either the primary site or in a metastatic focus 
suggests an intrinsic resistance and, at best, partial androgen sensitivity. Many pathways 
associated with resistance involve inhibition of proapoptotic molecules or the up-
regulation of cell-survival molecules.  
The androgen receptor (AR) is a member of a super-family of ligand-dependent 
transcription factors. Alterations in AR signaling that have been identified in human 
prostate cancer include alterations in steroid metabolism, an increase in the level of the 
protein, changes in co-regulator profiles, and ligand-independent activation. Changes in 
AR occur as the disease progresses from a clinically localized lesion in a non-castrate 
environment to a castrate metastatic lesion (Buchanan et al, 2001, Grossmann et al, 
2001, Scher et al, 2001). All of these mechanisms are consistent with continued 
signaling through the receptor in castration-resistant lesions. The AR protein is 
expressed in prostate cancers of all clinical states. In upwards of 30% of cases, levels 
are higher in castration-resistant as opposed to non-castrate tumors (Culig et al, 1998, 
Tilley et al, 1994). Amplification of the AR gene itself has also been reported in 
approximately 22% of castration-resistant metastases (Bubendorf et al, 1999) and in 
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23% to 28% of recurrent primary tumors and is associated with increased levels of the 
AR and the proteins it regulates (Koivisto et al, 1996, Linja et al, 2001). 
The most common mutations in the AR that have been identified in clinical 
specimens are in the ligand-binding domain. Virtually all are associated with a gain of 
function, as opposed to the loss of function mutations, which are most common among 
patients with androgen-insensitivity syndromes. Most disrupt a protein–protein 
interaction surface and result in an increase in the transactivation activity of the receptor 
in response to a range of classical and nonclassical ligands (Buchanan et al, 2000) 
In addition to steroid hormones, growth factors, such as keratinocyte growth 
factor, IGF–1, and EGF; HER2; and cytokines, such as interleukin–6 (IL–6), can 
activate the AR independent of ligand (Culig et al, 1994, Ueda et al, 2002). Exactly how 
these factors activate signaling is an area of active study. This can also contribute to 
progression in castration-resistant disease.  
Inhibitors of apoptosis are also implicated in the acquisition of the castration-
resistant phenotype. Blocking cell death pathways that are normally induced by 
androgen ablation allows cells to survive. bcl–2, which inhibits the death of cancer cells 
without affecting their rate of proliferation, is essentially undetectable in most non-
castrate lesions but is highly expressed in castration-resistant disease (McDonnell et al, 
1992). Similarly, survivin, a member of the class of proteins called inhibitors of 
apoptosis, is highly expressed in benign and malignant prostate neuroendocrine cells 
(Xing et al, 2001).  
Bone Metastasis 
Bone metastases represent a major health and financial burden because of their 
frequency and the considerable morbidity they generate in cancer patients. They occur 
commonly in patients with advanced prostate carcinoma, affecting at least 70% of 
patients with metastatic disease (Adami et al, 1997).  
Prostate cancer cells that have gained access to the circulation have a unique 
predilection for bone. The establishment of a metastatic focus in bone involves multiple 
steps, including adhesion of the tumor cells to endothelial cells in the marrow and 
migration through fenestrations in the endothelial cell layer. This migration is driven, in 
part, by a chemo attractant gradient of marrow- and stromal-derived growth factors. 
Once established, tumor cells and marrow-derived cells develop a bidirectional 
interaction that protects the epithelial cells and promotes tumor cell survival and 
proliferation (Cher et al, 2001). 
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Factors that contribute to cancer growth in bone are broadly divided into 
osteoblastic and osteolytic factors. Sources include the tumor cells themselves, normal 
bone cells, and reserves in the bone matrix that are released as part of the remodeling 
process. Many of the factors contributing to the osteoblastic phenotype, such as 
endothelin–1 (ET–1) (Nelson et al, 2003) and IL–6 can be targeted directly. ET–1, 
produced by prostate cells, stimulates the differentiation of osteoblast precursors, 
decreases osteoclastic bone resorption and motility, and augments the mitogenic effects 
of IGF–1, IGF–2. In normal bone, osteoblasts regulate osteoclastogenesis by interacting 
with mononuclear hematopoietic precursors. Osteoblasts express receptor activator of 
nuclear factor B ligand (RANKL) and osteoprotegerin. Osteoprotegerin level increases 
in patients with bone metastases (Jung et al, 2003). IL–6 is another cytokine released by 
prostate cancer cells that contributes to increased bone resorption (Keller et al, 2004). 
Binding of RANKL to RANK on osteoclastic precursors initiates intracellular signals 
that activate an osteoclastic phenotype.  
Management of Prostate Cancer 
The management of all stages of prostate cancer is sometimes highly 
contraversial. This disease often has a long natural history; therefore, substantial 
numbers of patients survive 15 years or longer after the diagnosis (even without 
treatment). Furthermore, because the disease occurs in older men, a large number of 
patients die from these conditions before they suffer symptoms or die from prostate 
cancer. Investigators and clinicians vary widely in their use of surgery, radiotherapy, 
hormonal manipulation, and other measures for treating each stage of disease. Most 
clinicians agree, however, that treatment of early stage disease with either surgery or 
radiotherapy results in comparable survival. It is unclear at time whether similar 
survival rates could be achieved with systemic therapies. 
Endocrine therapy is mainstay of treatment for symptomatic advanced prostate 
cancer. Patients with asymptomatic advanced disease do not appear to have improved 
survival with treatment when compared with untreated cells. Thus, treatment of patients 
with asymptomatic, advanced disease is not essential. Orchiectomy (removal of testicles 
by surgery), luteinizing hormone-releasing hormone (LHRH) agonists, and 
antiandrogens are the available treatments.
 
After androgen ablation treatment, usually 
prostate cancer cells undergo an active process of programmed cell death (apoptosis).
 
Unfortunately, within 18–24 months after starting this treatment %80 relapse occurs and 
cells will be adept to survive without androgenic stimulation and become unresponsive 
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to androgen withdrawal. The mechanism responsible for development of androgen-
independent cancer is not clear yet. Accumulating evidence suggests that growth factors 
and cytokines play an important role in this mechanism.
 Other agents that may be helpful in management of prostate cancer include the 
following; progestins, corticosteroids, zoledronic acid for reduction in bone pain, in 
time to first skeletal related events and other drugs that inhibit androgen synthesis such 
as aminoglutethimide or ketoconazole. Chemotherapy also provides relief in 20 % to 
30% of symptomatic patients with prostate cancer. Estramustine, cisplatine, 5-
fluorouracil, vinorelbine, gemcitabine, paclitaxel are the most popular agents. 
 
1.2 Zoledronic Acid  
 
Bisphosphonates are pyrophosphate analogues in which a carbon atom has 
replaced the oxygen bridge. They bind strongly to hydroxyapatite in bone. The addition 
of different carbon side chains has generated a diverse group of compounds that can 
inhibit bone resorption via actions on the osteoclast. The more recently developed 
nitrogen containing bisphosphonates; such as pamidronate and zoledronic acid, have 
greatly enhanced potency. Zoledronic acid is a nitrogen-containing bisphosphonate that 
inhibits osteoclast activity and bone resorption. It is indicated for the treatment of 
hypercalcemia of malignancy and for the treatment of patients with multiple myeloma 
and patients with documented metastasis from solid tumors, in conjunction with 
standard antineoplastic therapy. Zoledronic acid is structurally similar to other 
bisphosphonates, having the required phosphorus-carbon-phosphorus core and a 
hydroxyl group at the R1 position (Green et al, 2001). However, it is the heterocyclic 
imidazole group attached to the R2 position that distinguishes zoledronic acid from 
other bisphosphonates (Widler et al, 2002). The chemical structure of zoledronic acid is 
shown in the Figure 1.1. 
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Figure 1.1. Chemical structure of zoledronic acid 
(Source: Zometa®, insert package) 
 
Bone metastases represent a major health and financial burden because of their 
frequency and the considerable morbidity they generate in cancer patients. They occur 
commonly in patients with advanced prostate carcinoma, affecting at least 70% of 
patients with metastatic disease (Adami et al, 1997). After development of hormone-
refractory metastatic disease, prostate cancer is incurable. The metastasis of prostate 
cancer cells to the bone marrow constitutes the major source of morbidity and mortality 
in prostate cancer (Singh et al, 2006).  Excessive osteoclast activity plays a central role 
in the pathophysiology of bone disease at each stage of prostate cancer disease 
progression (Saad et al, 2006). The bone marrow microenvironment is strictly involved 
in the evolution of the prostate disease progression by supporting cell growth and 
survival (Corso et al, 2005). Tumor cells then release a variety of growth factors that 
promote bone resorption and increase the risk of skeletal complications (Lipton, 2004). 
The activation of some signaling pathways within the bone stromal cells increases the 
productions of several cytokines which in turn favors the cell proliferation and survival 
and enhance the drug resistance by anti-apoptotic mechanisms (Corso et al, 2005). 
Bisphosphonates have become a new form of medical therapy for tumor bone 
disease (Body et al, 1998, Powles et al, 2002). They are successfully used to treat the 
symptoms of metastatic bone disease, especially bone pain, and they reduce by up to 
40% the long-term skeletal morbidity rate. Bisphosphonates interfere as well with bone 
microenvironment inhibiting the survival of stromal cells and hampering the contact 
between plasma and stromal cells (Corso et al, 2005). Zoledronic acid, a new-generation 
bisphosphonate is mainly osteolysis-inhibitory agent (Brubaker et al, 2006). These 
agents act primarily by initiating biochemical processes that ultimately result in 
apoptosis of osteoclasts, but they also have a number of other antitumor functions (eg, 
inhibition of angiogenesis) (Conte et al, 2004). Osteoclast inhibition was obtained with 
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bone-targeted zoledronic acid (Gao et al, 2005). Bisphosphonates are potent inhibitors 
of osteoclast activity that have demonstrated efficacy in the treatment of bone 
metastases (Lipton, 2004). Bisphosphonates bind eagerly to the bone matrix, are 
released during bone resorption, and are subsequently internalized by osteoclasts, where 
they interfere with biochemical pathways and induce osteoclast apoptosis (Lipton, 
2004). Bisphosphonates also antagonize osteoclastogenesis and promote the 
differentiation of osteoblasts. As a result, bisphosphonates inhibit tumor-induced 
osteolysis and reduce skeletal morbidity (Lipton, 2004). 
Zoledronic acid, a highly potent inhibitor of osteoclast-mediated bone 
resorption, has increased bone mineral density in men receiving androgen deprivation 
therapy and is the only bisphosphonate that has shown statistically significant 
reductions in skeletal morbidity in patients with bone metastases from prostate cancer 
(Saad et al, 2006). Due to its unique properties, zoledronic acid is a breakthrough in the 
management of metastatic bone disease in patients with advanced prostate cancer 
(Hoesl et al, 2006). Zoledronic acid should be considered for the prevention of skeletal 
morbidity in patients with prostate cancer throughout their treatment continuum (Saad et 
al, 2006).  
Nitrogen containing bisphosphonates (e.g., pamidronate, ibandronate, zoledronic 
acid) inhibit protein prenylation, thus affecting cell function and survival (Green, 2003). 
In vitro, submicromolar concentrations of bisphosphonates inhibited tumor cell 
adhesion and reduced invasion through extracellular matrix. At higher concentrations, 
antiproliferative and proapoptotic effects have been reported (Green, 2003). 
Bisphosphonates exert their effects on osteoclasts and tumor cells by inhibiting a key 
enzyme in the mevalonate pathway, farnesyl diphosphate synthase, thus preventing 
protein prenylation and activation of intracellular signaling proteins such as Ras (Green, 
2004). Recent evidence suggests that bisphosphonates also induce production of a 
unique adenosine triphosphate analogue (Apppi) that can directly induce apoptosis 
(Green, 2004). Their biochemical effects on protein prenylation, they induce caspase-
dependent apoptosis, inhibit matrix metalloproteinase activity, and down regulate alpha 
(v) beta (3) and alpha (v) beta (5) integrins (Green, 2004). 
Zoledronic acid also inhibits tumor cell adhesion to the extracellular matrix and 
has anti-angiogenic activity (Green, 2004). 
Preclinical evidence suggests that zoledronic acid has antitumor activity in 
prostate cancer models probably due to their ability to interfere with several intracellular 
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signaling molecules (Melis et al, 2005, Saad et al, 2006, Green, 2005). Furthermore, 
preclinical studies suggest that bisphosphonates possess antitumor activity and can 
inhibit proliferation and induce apoptosis of tumor cell lines (Lipton, 2004). In addition, 
zoledronic acid, a new-generation bisphosphonate, appears to inhibit tumor cell 
invasion of the extracellular matrix (Lipton, 2004). 
Bisphosphonates work by inhibiting osteoclast-mediated bone resorption and 
have also demonstrated antitumor activity in preclinical models (Saad, 2005). 
Specifically, zoledronic acid inhibits proliferation and induces apoptosis of human 
prostate cancer cell lines in vitro (Green, 2005).  In a model of prostate cancer, 
zoledronic acid significantly inhibited growth of both osteolytic and osteoblastic tumors 
and reduced circulating levels of prostate-specific antigen. Bisphosphonates block the 
development of monocytes into osteoclasts and are thought to promote apoptosis of 
osteoclasts (Berenson, 2001). These agents prevent osteoclasts from moving to the bone 
surface and seem to inhibit the production of bone-resorbing cytokines such as 
interleukin-6 (IL-6) by bone marrow stromal cells (Berenson, 2001). 
The therapeutic benefits of biphosphonates in patients with advanced prostate 
were proved in several studies. Zoledronic acid (Zometa; Novartis Pharmaceuticals 
Corp.; East Hanover, NJ and Basel, Switzerland) exerts synergistic antitumor activity 
when combined with other anticancer agents (Green, 2004). It was shown that the 
combination of zoledronic acid with selective EGFR-tyrosine kinase inhibitor (gefitinib) 
causes a cooperative antitumor effect accompanied by induction of apoptosis and 
regulation of the expression of mitogenic factors, proangiogenic factors and cell cycle 
controllers both in vitro and in xenografted nude mice (Melisi et al, 2005). These results 
provide new insights into the mechanism of action of zoledronic acid and a novel 
rationale to translate this feasible combination treatment strategy into a clinical setting 
(Melisi et al, 2005). The experimental data based on combinations of zoledronic acid 
with either gemcitabine or fluvastatin indicates its therapeutic role in treatment of bone 
metastasis of selected malignancies (Budman et al, 2006). The recent history of 
chemotherapy has shown that combinatorial therapy by using specific inhibitors of 
dominantly active signaling pathways opens new treatment perspectives in metastastic 
tumors. These studies suggest that zoledronic acid has the potential to inhibit bone 
metastasis and bone lesion progression in patients with prostate cancer (Green, 2005). 
Recent studies have suggested that bisphosphonates may also exert direct 
antitumor effects on myeloma cells (Avcu et al, 2005). In vitro studies have 
 13 
demonstrated the antitumor potential of zoledronic acid on myeloma cell lines (Corso et 
al, 2005). Zoledronic acid is able to affect the isoprenylation of intracellular small G 
proteins (Caraglia et al, 2004). The antitumor activity of Zoledronic acid combined with 
R115777 farnesyl transferase inhibitor (FTI) against epidermoid cancer cells was 
increased (Caraglia et al, 2004). In human epidermoid head and neck KB and lung 
H1355 cancer cells, 48 h exposure to pamidronate and zoledronic acid induced growth 
inhibition (25 and 10 µM, respectively) and apoptosis and abolished the proliferative 
and antiapoptotic stimuli induced by epidermal growth factor (EGF) (Caraglia M et al, 
2004). 
Zoledronic acid induced apoptosis through the activation of caspase 3. A strong 
decrease of basal ras activity was observed. These effects were paralleled by impaired 
activation of the survival enzymes extracellular signal regulated kinase 1 and 2 (Erk-
1/2) and Akt that were not restored by EGF (Caraglia et al, 2004). 
The combined treatment with Zoledronic acid and R115777 resulted in a strong 
synergism both in growth inhibition and apoptosis in KB and H1355 cells. The 
combination was highly effective in the inhibition of ras, Erk and Akt activity, while 
farnesol again antagonized these effects (Caraglia et al, 2004). 
Zoledronic acid has been shown to inhibit the oncogenicity of Ras through the 
inhibition of prenylation of Ras and Ras-related proteins by the induction of S-phase 
cell cycle arrest and apoptosis (Chuah et al, 2005). Nitrogen containing-
bisphosphonates have direct antitumor effects via the inactivation of Ras proteins (Sato 
et al, 2005). Zoledronic acid also can exert an antiangiogenic activity and inhibition of 
tumor cell bone invasiveness by a transient reduction of VEGF, bFGF circulating levels 
after infusion (Ferretti et al, 2005). 
Although zoledronic acid is widely used in metastatic prostate cancer 
management, few data are available about its molecular effects in prostatic cells. The 
antitumor activity of biphosphonates that found in vitro and in vivo is interesting and 
has to be further assessed in laboratory and clinical studies. Further studies are needed 
to fully elucidate these biochemical mechanisms and to determine if the antitumor 
potential of bisphosphonates translates to the clinical setting. 
Bone metastasis microenvironment-related growth factors such as insulin-like 
growth factor 1 (IGF-1), transforming growth factor beta 1 (TGF-beta1), basic 
fibroblast growth factor (bFGF) and interleukin 6 (IL-6) show survival factor activity by 
inhibiting chemotherapy-induced apoptosis of PC-3 prostate cancer cells in vitro (Tenta 
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et al, 2005). Recently, zoledronic acid has been shown to induce apoptosis in PC-3 
prostate cancer cells (Tenta et al, 2005). These bone microenvironment-related growth 
factors, also can modify the actions of various pharmaceutical agents, including 
cytotoxic drugs in malignant cell lines (Tenta et al, 2006). Since bisphosphonates inhibit 
the proliferation and induce the apoptosis of certain prostate cancer cell lines, its 
mechanism of action is not clearly understood. IL-6 is an important cytokine on prostate 
cancer progression. One possible mechanism might be the IL-6 mediated pathway. The 
relation between zoledronic acid and IL-6 has not been known since there is no 
experimental data. 
 
1.3. Interleukin-6 in Prostate Cancer  
 
IL-6 is a 21–28 Kd cytokine containing 184 amino acids following cleavage of a 
28 aa signal peptide (May et al, 1988). IL-6 belongs to the ‘‘IL-6 type cytokine’’ family 
that also includes leukemia inhibitory factor, IL-11, ciliary neurotrophic factor, 
cardiotrophin-1 and oncostatin M (Sehgal et al, 1995). In the normal homeostatic state, 
IL-6 levels are typically very low. However, in response to the appropriate stimulus 
(e.g. inflammation); a wide variety of cells produce IL-6. Many physiologic functions 
are attributed to IL-6 including promotion of antibody production from B lymphocytes, 
modulation of hepatic acute phase reactant synthesis, promotion of osteoclastic- 
mediated bone resorption, and induction of thrombopoiesis (Hirano et al, 1992). In 
addition, it is implicated in development and progression of tumors of various organs, in 
particular myeloma, renal and prostate cancer, and melanoma. 
Multiple studies have demonstrated that IL-6 is elevated in the sera of patients 
with metastatic prostate cancer (Adler et al, 1999; Hoosein N et al, 1995; Twillie et al, 
1995). Adler et al demonstrated that serum levels of IL-6 and transforming growth 
factor-b1 are elevated in patients with metastatic prostate cancer, and that these levels 
correlate with tumor burden as assessed by serum PSA or clinically evident metastases. 
In a similar fashion, Drachenberg et al reported elevated serum IL-6 levels in men with 
hormone-refractory prostate cancer compared to normal controls, benign prostatic 
hyperplasia, prostatitis, and localized or recurrent disease (Drachenberg et al, 1999). 
These observations suggest that IL-6 may be a surrogate marker of the androgen 
independent phenotype. IL-6 has been shown to be a candidate mediator of prostate 
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cancer morbidity and a candidate marker of disease activity for prospective clinical 
testing (Twillie et al, 1995). In addition to its role as a mediator of morbidity, IL-6 may 
also act as a growth factor, and protect prostate cancer cells from cell death induced by 
certain chemotherapeutic agents. IL-6 has been implicated in the modulation of growth 
and differentiation in many malignant tumors and is associated with poor prognosis in 
several solid and hematopoietic neoplasms such as renal cell carcinoma, ovarian cancer, 
lymphoma, and melanoma (Siegall et al, 1990). Thus, taken together, these data provide 
a large body of evidence that IL-6 is associated with prostate cancer in the clinical 
arena. 
The androgen receptor (AR), which is expressed in normal prostate tissue and 
heterogeneously in prostate cancers, is a key transcription factor in the prostate 
(Hobisch et al, 1996; Hobisch et al, 1991; Van der Kwast et al, 1991). Activation of the 
AR in prostate cancer is being intensively investigated, and there is evidence that the 
AR could be stimulated by a number of nonsteroidal compounds, such as polypeptide 
growth factors, protein kinase A activators, vitamin D and neuropeptides (Culig et al, 
1994, 1997; Nakhla et al, 1997; Nazareth et al, 1996; Zhao et al, 1997). IL-6 activates 
the AR in a ligand-independent manner and induces a synergistic AR response with 
very low concentrations of androgen (Chen et al, 2000; Hobisch et al, 1998). The 
interaction between IL-6 and AR might be particularly important in patients with 
advanced prostate cancer who have elevated serum levels of IL-6 (Adler et al, 1999; 
Hoosein et al, 1995; Twillie et al, 1995). 
IL-6 and Signaling Pathways  
 IL-6 signals through the membrane receptor that is composed of the ligand-
binding subunit gp80 which forms a low affinity complex with the cytokine and the 
signal transduction subunit gp130. The gp130 subunit’s action is redundant since it is 
activated in response to IL-6-related cytokines, such as leukemia inhibitory factor (LIF) 
and IL-11. IL-6 receptors are expressed in a variety of benign and malignant cells. 
Following homodimerization of gp130, there is a formation of a hexameric complex 
consisting of two molecules each of IL-6, gp80, and gp130. This complex forms a high-
affinity binding site for IL-6. IL-6 signaling is enhanced by the soluble IL-6 receptor, 
which can form a fully hexameric complex. One reason for induction of different 
responses is the ability of IL-6 to activate signaling through distinct pathways. 
IL–6 is capable of activating three major proliferative pathways as shown in the 
Figure 1.2. The MAPK pathways and STAT transcription factor activation serves to 
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drive proliferation, as does the PI3K pathways. Activation of AKT inactivates many 
pro-apoptotic mediators. While this leads to cell survival in an immune related crisis, it 
can also lead to survival of DNA damaged cells, and potentially to neoplastic growth. 
In various cell types, IL-6 binding to its receptor leads to phosphorylation of 
Janus kinases (JAK) that in turn phosphorylate the gp130 receptor subunits. The next 
step in IL-6 signaling is translocation and phosphorylation of signal transducers and 
transcription (STAT) factors by JAK. Among these transcription factors, STAT3 has a 
predominant role in IL-6 signal transduction. The role of STAT3 in malignant 
transformation of several cell lines has been well documented (Horiguchi et al, 2002).  
Upon tyrosine phosphorylation, STATs (including STAT1, STAT3, and STAT5) 
translocate to the nucleolus as homodimers or heterodimers and bind to specific 
consensus DNA sequences of target-gene promoters and activate transcription (Fukada 
et al, 1996; Fourcin et al, 1996).  
Another signaling pathway of IL-6 involves the GTP binding protein Ras, which 
may also be involved in other cytokine systems. GTP-binding motifs are present in the 
gp130 intracytoplasmic region; however, their precise role is unclear (Hibi et al, 1990). 
This Ras-dependent pathway includes intermediate steps involving Raf, MEK and 
MAPK (Chen-Kiang et al, 1995, Ernst et al, 1996, Kishimoto et al, 1994, Kishimoto et 
al, 1995, Akira et al, 1990). Following translocation into the nucleus, it is believed that 
MAP kinase activates the nuclear factor for IL-6 (NF-IL6) transcription factor to act on 
its target genes (Akira et al, 1990). The binding activity of NF-IL6 is most likely 
induced by IL-6 through the increased expression of the NF-IL6 gene, rather than 
through post-translational modification (Matsumoto et al, 1998). Other serine: threonine 
protein kinases can also be activated by IL-6 (Yin et al, 1994). 
 Moreover, IL-6 also activates phosphatidylinositol (PI3)-kinase through the 
activation of the p-85 subunit of PI3-kinase and contributes to the complexity of the 
cellular response to this cytokine (Boulton et al, 1994, Chen et al, 1999, Takahashi-
Tezuka et al, 1997). Regulation of cell death by IL-6 is a subject of great importance. A 
typical feature of prostate cancer is a decreased rate of cell death. The PI3-K pathway is 
activated in response to IL-6 in PC-3 cells. This was demonstrated in experiments in 
which the tyrosine phosphorylation of p85, the regulatory subunit of the PI3-K was 
studied (Chung et al, 2000).  
 P85 coprecipitated with the signal-transducing subunit of the IL-6 receptor. IL-6 
thus contributes to an increase in phosphorylation of Akt, which is a typical feature of 
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aggressive prostate cancer. Akt phosphorylation in prostate cancer Gleason scores 6 or 7 
have a prognostic significance (Ayala et al, 2004).  
 
 
 
Figure 1.2. IL–6 and signaling pathways 
(Source: David et al, 2005.) 
 
Effects of IL- 6 on human prostate cancer cell lines  
Defining mechanisms to control IL-6 or IL-6R expression may prove useful for 
therapy of the many clinical disorders in which IL-6 plays a role (Keller et al, 1996). 
Addition of anti-IL-6 antibody to the growth medium of the hormone independent cell 
lines DU145, PC-3 (Chung et al, 1999, Borsellino et al, 1995) and TSU (Chung et al, 
1999) inhibits cell growth. In vitro studies have shown that the addition of anti-IL-6 
enhances the cytotoxicity of certain chemotherapeutic agents in PC-3 cells, which are 
resistant to the drugs alone (Borsellino et al, 1995). Borsellino et al. later showed that 
the activity of IL-6 was more efficiently blocked with an IL-6R antagonist, Sant7, and 
that this too potentiated the sensitivity of PC-3 cells to etoposide-mediated cytotoxicity 
(Borsellino et al, 1999). In this study, the investigators also blocked signaling through 
gp130 in PC-3 using a gp130 antisense oligodeoxynucleotide. This inhibited cell growth 
and viability by about 20% and increased sensitivity to etoposide, confirming the 
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positive role of endogenous IL-6 in cell survival (Borsellino et al, 1999). These data 
suggest that endogenous IL-6 acts to protect tumor cells from drug induced cell death, 
and its neutralization may be a useful adjuvant to chemotherapy. 
Studies of IL-6 expression in prostate cancer were initially carried out in a 
variety of prostate cancer cell lines. The androgen-refractory cell lines PC-3, DU145, 
and TSU secrete a number of cytokines including high levels of IL-6 (Chung et al, 
1999). IL-6 was also detected in the supernatants of cultured prostatic stromal and 
epithelial cells (Hobisch et al, 2000, Chung et al, 1999, Degeorges et al, 1996). There 
have been conflicting reports as to whether or not the androgen-responsive cell line 
LNCaP secretes IL-6. Some investigators have observed IL-6 production in this cell line 
(Keller et al, 1996, Siegall et al, 1990) while others have reported minimal or no IL-6 
production by LNCaP cells (Chung et al, 1999, Okamoto et al, 1997). In contrast to the 
conflicting data regarding IL-6, the presence of IL-6 receptor is more consistent. 
Specifically, the hormone refractory cell lines DU-145, PC-3 and TSU, and the 
hormone-dependent cell lines LNCaP, LNCaP-ATCC, and LNCaP-GW have been 
shown to express both components of the IL-6 receptor complex. 
Proliferation studies carried out with prostate cancer cell lines revealed different 
effects of IL-6 on androgen-sensitive and insensitive cells (Chung et al, 1999). Just as 
there have been contrasting results regarding the production of IL-6 by LNCaP cells, a 
number of studies from various laboratories have yielded contrasting results regarding 
the effects of IL-6 on the growth of these cells. Chung et al showed that inhibition of 
IL-6 resulted in decreased cell growth of hormone-refractory cells, but had no effect on 
the growth of hormone-dependent cell lines (Chung et al, 1999). Addition of exogenous 
IL-6 to the culture media of LNCaP cells by several groups has resulted in a dose-
dependent inhibition of cell growth (Chung et al, 1999, Degeorges et al, 1996, Ritchie et 
al, 1997, Hobisch et al, 2000). On the other hand, some researchers observed a 
stimulatory response after treatment with IL-6 (Qiu et al, 1998, Okamoto et al, 1997). 
The reasons for these differences have not been clarified to date but it seems that IL-6 in 
human prostate cancers exerts divergent effects and therefore it will be interesting to 
learn more about its co-localization with molecules that regulate cellular proliferation. It 
thus appears that IL-6 acts as an autocrine and paracrine growth factor in PC-3, TSU, 
and DU145 cells (Chung et al, 1999) and as a paracrine growth inhibitor in LNCaP cells 
(Chung et al, 1999, Degeorges et al, 1996). However, in the presence of androgen, IL-6 
acts as an autocrine growth factor in LNCaP cells (Okamoto et al, 1997). Applying 
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these findings to behavior of prostate cancer in vivo, Chung et al. have suggested that 
IL-6 may undergo a functional transition from paracrine growth inhibitor to autocrine 
growth stimulator during the progression of CaP to the hormone refractory phenotype 
(Chung et al, 1999). 
 
1.4. Characterization of PC-3 Prostate Cancer Cell Line  
 
The human hormone-independent prostate cancer cell line PC-3 was used 
(Figure 1.3.) which is derived from a bone metastasis of a grade IV prostatic 
adenocarcinoma from a 62-year-old male Caucasian (Kaighn et al, 1979). The cultured 
cells show anchorage-independent growth in both monolayers and in soft agar 
suspension and produce subcutaneous tumors in nude mice. Culture of the transplanted 
tumor yielded a human cell line with characteristics identical to those used initially to 
produce the tumor. Drug-resistant prostatic carcinoma cell-line PC-3 has a greatly 
reduced dependence upon serum for growth when compared to normal prostatic 
epithelial cells and does not respond to androgens, glucocorticoids, or epidermal or 
fibroblast growth factors. Karyotypic analysis by quinacrine banding revealed the cells 
to be completely aneuploid with a modal chromosome number in the hypotriploid 
range. At least 10 distinctive marker chromosomes were identified (Chen et al, 1993). 
The overall karyotypes as well as the marker chromosomes are distinct from those of 
the HeLa cell. Electron microscopic studies revealed many features common to 
neoplastic cells of epithelial origin including numerous microvilli, junctional 
complexes, abnormal nuclei and nucleoli, abnormal mitochondria, annulate lamellae, 
and lipoidal bodies.
 
They
 
have non-functional androgen receptor (AR), express the IL–6 
receptor (Tilley et al, 1990) also secrete IL–6 (Chung et al, 1999). 
Overall, the functional and morphologic characteristics of PC-3 are those of a 
poorly-differentiated adenocarcinoma. These cells should be useful in investigating the 
biochemical changes in advanced prostatic cancer cells and in assessing their response 
to chemotherapeutic agents.  
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Figure 1.3. Morphology of PC-3 cells under a microscope (10x) 
 
1.5. Methods for Studying Cytotoxicity 
 
Cytotoxicity is the cell-killing property of a chemical compound (such as a food, 
cosmetic, or pharmaceutical) or a mediator cell (cytotoxic T cell). In contrast to necrosis 
and apoptosis, the term cytotoxicity does not indicate a specific cellular death 
mechanism. For example, cell-mediated cytotoxicity (that is, cell death mediated by 
either cytotoxic T lymphocytes [CTL] or natural killer [NK] cells) combines some 
aspects of both necrosis and apoptosis (Berke et al, 1991; Krahenbuhl et al, 1991). 
Most current assays for measuring cytotoxicity are based on alterations of 
plasma membrane permeability and the consequent release (leakage) of components 
into the supernatant or the uptake of dyes, normally excluded by viable cells (“Dye 
exclusion method”). This permeability assays involve staining damaged cells with a dye 
and counting viable cells that exclude the dye. Counts can be performed manually using 
a hemocytometer. Counting cells by the use of a hemocytometer is a convenient and 
practical method of determining cell numbers and it gives us the opportunity to see what 
we are counting. If the cells were previously mixed with an equal volume of viability 
stain (e.g trypan blue) a viability determination may be performed at the same time. 
Most of the errors in this procedure occur by incorrect sampling and transfer of cells to 
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the chamber. Although the trypan stain distinction has been questioned, it is simple and 
gives a good approximation. 
This method is also inexpensive, and requires only a small fraction of total cells 
from a cell population. Therefore, it is generally used to determine the cell 
concentration (cell number/ml) in batch cell cultures. This is helpful in ensuring that 
cell cultures have reached the optimal level of growth and cell density before routine 
sub-culture, freezing, or any experiment (Berridge et al, 1993). 
A serious disadvantage of permeability assays is that the initial sites of damage 
of many, if not most cytotoxic agents are intracellular. Therefore, cells may be 
irreversibly damaged and committed to die and the plasma membrane is still intact. 
Thus, these assays tend to underestimate cellular damage when compared to other 
methods. Despite this fact, permeability assays have been widely accepted for the 
measurement of cytotoxicity. 
Alternatively, metabolic activity can be measured by adding tetrazolium salts to 
cells. These salts are converted by viable cells (metabolically active cells) to colored 
formazan dyes that are measured spectrophotometrically. In contrast dead cells are 
unable to metabolize tetrazolium salts. Thus, tetrazolium salt-based colorimetric assays 
detect viable cells exclusively. This allows the use of the colorimetric assays MTT, 
XTT, or WST-1 to measure cell survival. Because they are sensitive, these assays can 
readily be performed in a microplate with relatively few cells. Since a cytotoxic factor 
will reduce the rate of tetrazolium salt cleavage by a population of cells, these metabolic 
activity assays are frequently used to measure factor-induced cytotoxicity or cell 
necrosis (Mosmann et al, 1983, Mosmann et al 1989). Applications include: Assessment 
of growth-inhibitory or cytotoxic effects of physiological mediators, analysis of the 
cytotoxic and cytostatic effects of potential anti-cancer and other drugs, analysis of 
cytopathic effects of viruses and screening of compounds with potential anti-viral 
activity and screening of antibodies for growth-inhibiting potential. 
The most common used microplate-based metabolic activity assays are;  
• MTT Cell Proliferation Kit, in which metabolically active cells cleave the 
tetrazolium salt MTT to a water-insoluble formazan that can be solubilized and 
quantitated with an ELISA plate reader  
• XTT Cell Proliferation Kit, in which metabolically active cells cleave the 
modified tetrazolium salt XTT to a water-soluble formazan, which may be directly 
quantitated with an ELISA plate reader (Figure 1.4.) 
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• Cell Proliferation Reagent WST-1, a modified tetrazolium salt that can be 
cleaved by metabolically active cells to a water-soluble formazan, which may be 
directly quantitated with an ELISA plate reader  
 
 
 
Figure 1.4. Metabolization of XTT to a water soluble formazan salt by viable cells. 
(Source: Roche Applied Science®) 
 
1.6. Methods for Studying Apoptosis in Cell Populations 
 
Cell death can occur by either of two distinct mechanisms (Schwartzman et al, 
1993, Vermes et al, 1994) necrosis or apoptosis. The two mechanisms of cell death may 
briefly be defined: 
Necrosis (“accidental” cell death) is the pathological process which occurs when 
cells are exposed to a serious physical or chemical insult. Apoptosis (“normal” or 
“programmed” cell death) is the physiological process by which unwanted or useless 
cells are eliminated during development and other normal biological processes. 
There are many observable morphological and biochemical differences (Table 
1.1.) between necrosis and apoptosis (Vermes et al, 1994). Necrosis occurs when cells 
are exposed to extreme variance from physiological conditions (e.g., hypothermia, 
hypoxia) which may result in damage to the plasma membrane. Under physiological 
conditions direct damage to the plasma membrane is evoked by agents like complement 
and lytic viruses. 
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Table 1.1. Differential features and significance of necrosis and apoptosis. 
 
Necrosis Apoptosis 
Loss of membrane integrity Membrane blebbing, but no loss of integrity 
Begins with swelling of cytoplasm and 
mitochondria 
Begins with shrinking of cytoplasm and 
condensation of   nucleus 
 
Ends with total cell lysis Ends with fragmentation of cell into smaller bodies 
No vesicle formation, complete lysis Formation of membrane bound vesicles  
Random digestion of DNA (smear of DNA after 
agarose gel electrophoresis) 
Non-random mono- and oligonucleosomal length 
fragmentation of DNA (Ladder pattern after 
agarose gel electrophoresis) 
Postlytic DNA fragmentation Prelytic DNA fragmentation 
Affects groups of contiguous cells Affects individual cells 
Phagocytosis by macrophages Phagocytosis by adjacent cells or macrophages 
Significant inflammatory response No inflammatory response 
Loss of regulation of ion homeostasis Activation of caspase cascade 
 
Necrosis begins with an impairment of the cell’s ability to maintain homeostasis, 
leading to an influx of water and extracellular ions. Intracellular organelles, most 
notably the mitochondria, and the entire cell swell and rupture (cell lysis). Due to the 
ultimate breakdown of the plasma membrane, the cytoplasmic contents including 
lysosomal enzymes are released into the extracellular fluid. Therefore, in vivo, necrotic 
cell death is often associated with extensive tissue damage resulting in an intense 
inflammatory response (Van Furth et al, 1988). 
Apoptosis, in contrast, is a mode of cell death that occurs under normal 
physiological conditions and the cell is an active participant in its own demise (“cellular 
suicide”). It is most often found during normal cell turnover and tissue homeostasis, 
embryogenesis, induction and maintenance of immune tolerance, development of the 
nervous system and endocrine-dependent tissue atrophy. 
Cells undergoing apoptosis show characteristic morphological and biochemical 
features (Cohen et al, 1993). These features include chromatin aggregation, nuclear and 
cytoplasmic condensation, partition of cytoplasm and nucleus into membrane bound-
vesicles (apoptotic bodies) which contain ribosomes, morphologically intact 
mitochondria and nuclear material. In vivo, these apoptotic bodies are rapidly 
recognized and phagocytized by either macrophages or adjacent epithelial cells (Savill 
et al, 1989). Due to this efficient mechanism for the removal of apoptotic cells in vivo 
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no inflammatory response is elicited. In vitro, the apoptotic bodies as well as the 
remaining cell fragments ultimately swell and finally lyse. 
Scientists now recognize that most, if not all, physiological cell death occurs by 
apoptosis, and that alteration of apoptosis may result in a variety of malignant disorders. 
Consequently, in the last few years, interest in apoptosis has increased greatly. Great 
progress has been made in the understanding of the basic mechanisms of apoptosis and 
the gene products involved. Key elements of the apoptotic pathway include: 
Death receptors: 
Apoptosis has been found to be induced via the stimulation of several different 
cell surface receptors in association with caspase activation. For example, the CD95 
(APO-1, Fas) receptor ligand system is a critical mediator of several physiological and 
pathophysiological processes, including homeostasis of the peripheral lymphoid 
compartment and CTL mediated target cell killing. Upon cross-linking by ligand or 
agonist antibody, the Fas receptor initiates a signal transduction cascade which leads to 
caspase-dependent programmed cell death. 
Membrane alterations: 
In the early stages of apoptosis, changes occur at the cell surface and plasma 
membrane. One of these plasma membrane alterations is the translocation of 
phosphatidylserine (PS) from the inner side of the plasma membrane to the outer layer, 
by which PS becomes exposed at the external surface of the cell. 
 Protease cascade: 
Signals leading to the activation of a family of intracellular cysteine proteases, 
the caspases, (Cysteinyl-aspartate-specific proteinases) play a pivotal role in the 
initiation and execution of apoptosis induced by various stimuli. Different members of 
caspases in mammalian cells have been identified. Among the best-characterized 
caspases is caspase-1 or ICE (Interleukin-1-Converting Enzyme), which was originally 
identified as a cysteine protease responsible for the processing of interleukin-1 (IL-1). 
Mitochondrial changes:  
Mitochondrial physiology is disrupted in cells undergoing either apoptosis or 
necrosis. During apoptosis mitochondrial permeability is altered and apoptosis specific 
protease activators are released from mitochondria. Specifically, the discontinuity of the 
outer mitochondrial membrane results in the redistribution of cytochrome C to the 
cytosol followed by subsequent depolarization of the inner mitochondrial membrane. 
Cytochrome C (Apaf-2) release further promotes caspase activation by binding to Apaf-
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1 and therefore activating Apaf-3 (caspase 9). AIF (apoptosis inducing factor), released 
in the cytoplasm, has proteolytic activity and is by itself sufficient to induce apoptosis. 
DNA fragmentation: 
The biochemical hallmark of apoptosis is the fragmentation of the genomic 
DNA, an irreversible event that commits the cell to die and occurs before changes in 
plasma membrane permeability (prelytic DNA fragmentation). In many systems, this 
DNA fragmentation has been shown to result from activation of an endogenous Ca2+ 
and Mg2+ - dependent nuclear endonuclease. This enzyme selectively cleaves DNA at 
sites located between nucleosomal units (linker DNA) generating mono- and 
oligonucleosomal DNA fragments (Figure 1.4). In contrast, the DNA of the 
nucleosomes is tightly complexed with the core histones H2A, H2B, H3 and H4 and 
therefore is protected from cleavage by endonuclease (Burgoyne et al, 1974, Stach et al, 
1979). The DNA fragments yielded are discrete multiples of a 180 bp subunit which is 
detected as a “DNA-ladder” on agarose gels after extraction and separation of the 
fragmented DNA. The enrichment of mono- and oligonucleosomes in the cytoplasm of 
the apoptotic cells is due to the fact that DNA degradation occurs several hours before 
plasma membrane breakdown (Duke et al, 1986, Bonfoco et al, 1995). 
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Figure 1.5.  The biochemistry of DNA fragmentation and the appearance of the “DNA 
ladder”. (Source: Roche Applied Science®) 
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A number of methods have now been developed to study apoptosis in cell 
populations. Because DNA cleavage is a hallmark for apoptosis, assays which measure 
prelytic DNA fragmentation are especially attractive for the determination of apoptotic 
cell death. The DNA fragments may be assayed in either of two ways: 
-As “ladders” (with the 180 bp multiples as “rungs” of the ladder) derived from 
populations of cells. In this assay, DNA has to be isolated and analyzed by simple 
agarose gel in order to detect fragmented DNA in cells. 
-By quantification of histone-complexed DNA fragments (mono- and 
oligonucleosomes) with an ELISA. It is an alternative method which circumvents the 
isolation and electrophoretic analysis of DNA, and is the immunological detection of 
DNA fragments by an immunoassay. 
 
1.7.  Methods for Measuring Interleukin-6 in the Supernatant of Cell 
Culture 
 
Enzyme Linked Immunosorbent Assay (ELISA) combine the specificity of 
antibodies with the sensitivity of simple enzyme assays, by using antibodies or antigens 
coupled to an easily assayed enzyme that possesses a high turnover number. ELISA can 
provide a useful measurement of antigen or antibody concentration. 
One of the most useful of the immunoassays is the two antibody “sandwich” 
ELISA. This assay is used to determine the antigen concentration in unknown samples. 
This ELISA is fast and accurate, and if a purified antigen standard is available, the assay 
can determine the absolute amount of antigen in an unknown sample. The sandwich 
ELISA requires two antibodies that bind to epitopes that do not overlap on the antigen. 
This can be accomplished with either two monoclonal antibodies that recognize discrete 
sites or one batch of affinity-purified polyclonal antibodies. 
To utilize this assay, one antibody is purified and bound to a solid phase 
typically attached to the bottom of a plate well. Antigen is then added and allowed to 
complex with the bound antibody. Unbound products are then removed with a wash, 
and a labeled second antibody is allowed to bind to the antigen, thus completing the 
“sandwich”. The assay is then quantitated by measuring the amount of labeled second 
antibody bound to the matrix, through the use of a colorimetric substrate by ELISA 
microplate reader (Figure 1.6). Major advantages of this technique are that the antigen 
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does not need to be purified prior to use, and that these assays are very specific. 
However, one disadvantage is that not all antibodies can be used. Monoclonal antibody 
combinations must be qualified as “matched pairs”, meaning that they can recognize 
separate epitopes on the antigen so they do not hinder each other’s binding. 
 
 
 
Figure 1.6. ELISA microplate reader 
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CHAPTER 2 
 
MATERIALS AND METHODS 
 
In this study, cell culture technique was used in order to grow prostate cancer 
cells, in vitro. The term cell culture refers to a culture derived from dispersed cells taken 
from original tissues, from a primary culture, or from a cell line or cell strain by 
enzymatic, mechanical, or chemical disaggregation. The major advantage of cell culture 
is control of the physiochemical environment (pH, temperature, osmotic pressure) also 
large quantities of well-defined cells can be obtained by using this technique.  
 
2.1 Materials 
 
The chemicals, reagents and kits used in our experiments are shown in Table 
2.1. In The human hormone-independent prostate cancer cell line PC-3 was generously 
supplied by Dr Levent Türkeli Marmara University, stanbul, Turkey. Zoledronic acid 
was obtained from Novartis Pharmaceuticals (Basel, Switzerland). 1mM stock solution 
of zoledronic acid was prepared by dissolving 4,016 mg dry powder zoledronic acid in 
10 mL distilled water and aliquots were stored in -20º C. Because zoledronic acid acts 
as a chelating agent on Ca++ in cell culture media, also we assessed the effects of the 
knowing chelating agent, EDTA (1-100µM) on the growth of PC-3 cells, under 
identical experimental conditions. Laboratory equipments required in this study are 
shown in Table 2.2. 
 29 
Table 2.1. List of chemicals used in experiments. 
 
Chemicals  Trademark 
RPMI 1640 with L-glutamine Biological Industries 
DMSO Sigma Chemical Co. 
Heat inactivated  fetal bovine serum Biological Industries  
EDTA Sigma Chemical Co. 
Tyripsin-EDTA Sigma Chemical Co. 
Penicillin Biological Industries 
Streptomycin Biological Industries  
Trypan-Blue  Sigma Chemical Co. 
Zoledronic acid Novartis Pharma AG 
Cell Proliferation Kit II (XTT) Roche Diagnostic GmBH 
Apoptosis Cell Death Detection ELISA PLUS Kit Roche Diagnostic GmBH 
Apoptotic DNA Ladder Kit Roche Diagnostic GmBH 
Human IL-6 ELISA Kit Biosource Inc. 
 
 
Table 2.2. List of equipments used in experiments. 
 
Equipments Trademark 
Laminar-Flow Hood NuAire,USA 
CO2 Incubator NuAire,USA 
Inverted Microscope Olympus,Japan 
Light Microscope Olympus,Japan 
Hemocytometer Neubauer 
Pipettors ( 10,20,100,1000µl) Eppendorf 
Plate Reader Medispec ESR 200 
Culture vessels Corning 
Pipetting Aid Eppendorf 
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2.2 Methods  
 
2.2.1 Cell Culture of PC-3 Cell Line 
 
The human hormone-independent and drug-resistant prostatic carcinoma cell-
line PC-3 was maintained in culture as adherent cells and cultured in Roswell Park 
Memorial Institute 1640 (RPMI 1640, Biological Industries, Israel) plus 5% heat 
inactivated fetal bovine serum (Biological Industries, Israel) added to 1% L-glutamine 
(Biological Industries, Israel) 1% nonessential amino acids (Biological Industries, 
Israel), 10.000 U/mL penicillin (Biological Industries, Israel) and 10 mg/mL 
streptomycin (Biological Industries, Israel). All cells were grown in humidified 
atmosphere at 37C° in 5% CO2. When the tumor cells were used as target cells, they 
were treated with trypsin–EDTA (Sigma Chemical Co.), washed, and resuspended in 
complete medium. 
 
2.2.2 Assessment of Cytotoxicity Produced by Zoledronic Acid. 
 
Trypan blue dye exclusion assay and XTT proliferation assay was used to 
confirm the drug-mediated cytotoxicity of zoledronic acid on PC-3 cells. 
 
2.2.2.1 Trypan Blue Dye Exclusion Assay 
 
Trypan Blue Dye Exclusion assay was used to assess the cytotoxic effect of 
zoledronic acid on PC-3 cells. This assay was also used to measure the proportion of 
viable cells following a potentially traumatic procedure, such as disaggregation, cell 
separation, or freezing and thawing during the cell culture. Briefly, assay involves 
staining damaged cells with a dye and counting viable cells that exclude the dye. Counts 
were performed manually using a hemocytometer and trypan blue (Figure 2.1). 
The hemocytometer consists of two chambers, each of which is divided into nine 
1.0 mm squares. A cover glass is supported 0.1 mm over these squares so that the total 
volume over each square is 1.0 mm x 0.1 mm or 0.1 mm3, or 10-4 cm3.  Since 1 cm3 is 
approximately equivalent to 1 ml, the cell concentration per ml will be the average 
count per square x 104.  In order to determine the ability of zoledronic acid to inhibit the 
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growth of PC-3 cells, cells were plated at a cell density of 6x 103 cells/well in 24-well 
plates and grown with RPMI containing 5% FBS. Cells then treated with zoledronic 
acid in a dose- (10, 60, and100 µM) and time-dependent manner (24, 48, 72 hr). After 
incubation period, 50 µL cells were taken and mixed with an equal volume of trypan 
blue [0.4% (w/v) trypan blue in PBS]. Then this suspension was loaded to the counting 
chamber of hemocytometer. Using the microscope with a 10X ocular, the numbers of 
unstained cells (viable cells) in the 4 outer squares were counted. Then the numbers of 
viable cells per mL were calculated. Counting was repeated in order to check 
reproducibility. The cell concentration was calculated as follows:  
 
Cell concentration per milliliter = average count per square x 104 
 
 
Figure 2.1. Measurement of cytotoxicity by counting the cells with a hemocytometer. 
(Source: Roche Applied Science®) 
 
2.2.2.2 XTT Proliferation Assay 
 
The effect of zoledronic acid (1-100µM) on PC-3 cell proliferation was 
investigated using a commercially available XTT proliferation kit (Roche Applied 
Science, Penzberg, Germany). The assay is based on the cleavage of the yellow 
tetrazolium salt XTT to form an orange dye by metabolic active cells (Gerlier et al, 
1986). While living (metabolically active) cells reduce tetrazolium salt to colored 
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formazan compound; dead cells do not. The formazan dye formed is soluble in aqueous 
solutions and is directly quantified using an ELISA microplate reader. 
Briefly, the cells were plated in 96-well culture plates (Corning Glass Works, 
Corning, N.Y, USA) at a density of 1000 cells/well in 200-µl RPMI culture medium 
after verifying cell viability by trypan blue (Sigma Chemical Co.) dye exclusion test. 
After incubation with zoledronic acid for 48 and 72 hr, 50 µl of XTT labeling mixture 
(sodium3’-[1-(phenyl-aminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene 
sulfonic acid hydrate and N-methyl dibenzopyrazine methyl sulfate; mixed in 
proportion 50:1) was added to the each well. Then cells were incubated with this 
mixture for 4 hr in a humidified atmosphere. The optical density was measured at 450 
nm with a reference wavelength at 650 nm in a Medispec ESR 200 microplate reader. 
The percentage of cytotoxicity was calculated as follows: 
          % Cytotoxicity = 1- (A of experimental well/ A of positive control well) x100 
 
 
 
Figure 2.2. Measurement of metabolic activity using the tetrazolium salt XTT 
(Source: Roche Applied Science®) 
+ XTT 
ELISA Reader 
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2.2.3 Evaluation of Apoptosis Induced by Zoledronic Acid 
 
Mono-oligo nucleosome detection-based ELISA and DNA fragmentation on 
simple agarose gel electrophoresis assays were used to evaluate the apoptosis. 
 
 2.2.3.1 Mono-Oligo Nucleosome Detection-based ELISA 
 
The commercially available Cell Death Detection ELISA kit (Roche Applied 
Science, Penzberg, Germany) was used to detect DNA fragmentation according to 
manufacturer’s instructions (Aragene et al, 1998). This nonradioactive immunoassay 
has been designed for relative quantification of DNA fragmentation in cells and it 
measures the enrichment of histone-complexed DNA fragments (mono- and 
oligonucleosomes) in the cytoplasm of apoptotic cells.  
Briefly, cytoplasmic lysates from control and zoledronic acid treated cells were 
transferred to a streptavidin-coated plate that was supplied with the kit. They were 
incubated for 2 hr in the presence of the immune reagent containing the antibodies 
against the histone proteins and DNA fragments (Anti-histone-biotin and Anti-DNA-
POD). During the incubation period, the Anti-histone antibody bound to the histone-
component of the nucleosomes and simultaneously captured the immunocomplex to the 
streptavidin-coated plate via its biotinylation. Additionally, the Anti-DNA-POD 
antibody reacted with the DNA component of the nucleosomes. After the removal of 
unbound components by a washing step, quantitative determination of the amount of 
nucleosomes was measured by the POD retained in the immunocomplex. POD is 
determined photometrically with ABTS as substrate, which then was read for optical 
density at 405 nm with a reference wavelength at 490 nm (Figure 2.3.). The enrichment 
of histones and DNA fragments in cell lysates were evaluated as indicator of apoptosis.  
The degree of apoptosis was displayed as percentage according to positive control cells.  
 
 
 
 
 
 
 34 
 
 
 
 
Figure 2.3. How the Cell Death Detection ELISAPLUS works. (Sample preparation and 
ELISA) (Source: Roche Applied Science®) 
 
2.2.3.2 DNA Fragmentation on Simple Agarose Gel  
 
The Apoptotic DNA Ladder Kit (Roche Diagnostic, Mannheim, Germany) was 
used to detect the typical DNA ladder formation in zoledronic acid treated cells, which 
is the hallmark of apoptotic cells. DNA fragments reveal, upon agarose gel 
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supernatant, which may contain 
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membrane during the incubation. 
 
Incubate cells with lysis buffer. 
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Streptavidin 
coated well 
Anti-histone 
biotine   
Sample 
containing 
nucleosomes 
Anti- 
DNA 
Peroxi
dase  
ABTS 
Substrate 
 35 
electrophoresis, a distinctive ladder pattern consisting of multiples of an approximately 
180 bp subunit.  
Firstly PC-3 cells were plated at a cell density of 2x 106 cells/well in 24-well 
plates and grown with RPMI containing 5% FBS and then treated with different 
concentration of zoledronic acid (1,10,60 and 90 µM) for 48 and 72 hr. After lysis of 
cultured cells in binding buffer, the cell lysates is applied to a filter tube with glass fiber 
fleece and passaged through the glass fiber by centrifugation. During this procedure 
nucleic acids bind specifically to the surface of glass fibers in the presence of chaotropic 
salts (Vogelstein et al, 1979). Residual impurities were removed by a wash step and 
subsequently DNA was eluted in elution buffer. The DNA is stable and can be used 
directly or stored at -20º C for later analysis.  
For gel electrophoresis, DNA samples and positive control (apoptotic U937 
cells) were run on 1% agarose gel stained with ethidium bromide. The voltage was set 
to 75V for 2 hours. DNA ladders indicative of nucleosomal DNA fragmentation became 
apparent after 2 hours. DNA ladders were visualized by placing gel onto an UV light 
source and photographed. 
 
2.2.4 Detection of IL–6 Levels by ELISA 
 
The Human IL-6 ELISA Kit (Biosource Inc., California, USA) was used for the 
quantititative determination of IL-6 in the supernatant from zoledronic acid treated PC-3 
cells.  Hu IL-6 kit is a solid phase sandwich ELISA. A monoclonal antibody specific for 
Hu IL-6 has been coated onto the wells of the microtiter strips provided. Samples, 
including standards of known Hu IL-6 content, control specimens, and unknowns, are 
pipetted into these wells, followed by the addition of a biotinylated monoclonal second 
antibody. During the first incubation, the Hu IL-6 antigen binds simultaneously to the 
immobilized antibody on one site, and to the solution phase biotinylated antibody on a 
second site. After removal of excess second antibody,  Streptavidin- Peroxidase enzyme 
is added. This binds to the biotinylated antibody to complete the four-member 
sandwich. After a second incubation and washing to remove the entire unbound 
enzyme, a substrate solution is added, which is acted upon by the bound enzyme to 
produce color. The intensity of this colored product is directly proportional to the 
concentration of Hu IL-6 present in our sample.  
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Briefly, PC-3 cells were cultured for 24,48,72 hr at a concentration of 1x105 
cells/ml of RPMI medium supplemented with 5% FBS. Then cells were incubated in the 
same medium in the absence or presence of zoledronic acid (1, 10, 60, 90,100µM). 
Supernatants were collected for all culture conditions and stored at -20°C until the day 
of the assay. Before thawing the supernatants, Hu IL-6 standards was prepared by 
making serial dilutions of 500, 250, 125, 62.5, 31.2, 15.6 and 7.8 pg/mL Hu IL-6. 100 
µL of supernatants and standards were added to the microplate wells. Then 50 µL of 
biotinylated anti-IL-6 solution was added into each well and plate was incubated for 2 
hours at RT. After the washing, 100 µL Streptavidin-HRP working solution was added 
to each well and plate was incubated with this solution 30 minutes at RT. After washing 
thoroughly, 100 µL of Stabilized Chromogen was added to each well. The liquids in the 
wells began to turn blue. Plate was incubated for 30 minutes at room temperature and in 
the dark. By adding 100 µL of Stop Solution to each well process is completed and the 
solutions in the wells changed from blue to yellow (Figure 2.4.). The absorbance was 
measured at 450nm with ELISA microplate reader. The absorbance of the standards 
against the standard concentration was plotted on a graph paper and the best smooth 
curve trough these points was drawn to construct the standard curve. The Hu IL-6 
concentrations for unknown samples were read from the standard curve. 
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Figure 2.4. Human IL-6 assay summary 
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2.3. Statistical Analysis 
 
All assays were set up in triplicate and the results were expressed as the 
mean+SD. Analysis of variance (one-way ANOVA) statistical methodology was 
performed to elucidate the mean effect of ZA treatment on IL-6 levels. 
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CHAPTER 3 
 
 
RESULTS AND DISCUSSIONS 
 
3.1. Results 
 
Two different methods were used to confirme the cytotoxic effect of zoledronic 
acid on PC-3 cells. First, trypan blue dye exclusion assay was used to determine the 
inhibition of proliferation of PC-3 cells by zoledronic acid. After treatment of various 
concentration of zoledronic acid, cells were stained with trypan blue and then counted 
with hemocytometer. The addition of trypan blue helps to distinguish viable, unstained 
cells from non-viable, blue-stained cells (Figure 3.1.). The number of viable cells was 
calculated as previously described. Our data proved that the cytotoxic effect of 
zoledronic acid was dose and time dependent in PC-3 cells (Figure 3.2.).  
 
 
 
Figure 3.1. Trypan blue dye exculision assay (VC: Viable cell, DC: Dead cell) 
 
 


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In concert with trypan blue exclusion assay, XTT proliferation assay have 
confirmed the ability of zoledronic acid to inhibit the growth of PC-3 cells in a dose and 
time dependent manner (48 and 72 hr). Identical experiments with increasing doses of 
zoledronic acid produced an inhibition of the growth of PC-3 cells, at drug 
concentrations as low as 10 µM (48 and 72 hr) (Figure 3.3.). 
 
         
 
Figure 3.2.  Cell counts of viable PC-3 cells as measured by trypan blue exclusion 
assay with zoledronic acid (100 µM for 24, 48 and 72 hr) 
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Figure 3.3.  Dose–dependent cytotoxic activities of zoledronic acid against PC-3 cells 
(48 and 72 hrs) 
 
We tested the apoptotic effect of zoledronic acid on PC3- cells by using two 
different apoptosis measurement assay. It was shown that zoledronic acid induces 
apoptosis and this effect was time and dose dependent manner as displayed in Figure 
3.3. and 3.4. 
First, the apoptotic effect of zoledronic acid was measured by Cell Death 
Detection ELISA kit (Roche Applied Science, Penzberg, Germany), and displayed as 
the percentage values based on positive control data. Apoptotic effect was dependent on 
time and dose exposure (1, 10, 60, 90, 100 µM) in PC-3 cells (Figure 3.4.). 
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Figure 3.4. Evidence of the apoptotic effect of zoledronic acid (48 hrs). 
 
Then apoptotic effect of zoledronic acid was assessed by Apoptotic DNA Ladder 
Kit (Roche Applied Science, Penzberg, Germany). The cells were cultured for 48 and 
72 hr with various concentrations of zoledronic acid (1, 10, 60, 90, 100 µM). 
Fragmented DNA extracted from the cells was analyzed by agarose gel electrophoresis. 
Zoledronic acid (90 and100 µM for 72 hr) produced the classical DNA ladders on 
agarose gel characteristic of PC-3 cells undergoing apoptosis (Figure 3.4.). 
 
 
 
Figure 3.5.  DNA fragmentation analysis of zoledronic acid treated PC-3 cells using 
simple agarose gel electrophoresis. 
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IL-6 levels produced in vitro by PC-3 cells were determined using The Human 
IL-6 ELISA Kit (Biosource Inc., California, USA). PC-3 cells produced 24.04 ± 2.6 
pg/ml IL-6 (72 hr), under normal culture conditions in the absence of zoledronic acid. 
PC-3 cells were incubated with various concentrations of zoledronic acid (1, 10,30 , 60, 
90, 100 µM ) for 24,48 and 72 hrs. Then IL-6 levels were measured in supernatants of 
cell culture. IL-6 concentrations secreted by PC3 cells in the treatment of various 
zoledronic acid concentrations were lowered from 24 ± 0.4 pg/ml to 7 ± 0.8 pg/ml 
(Table 3.1.).  
 
Table 3.1. IL-6 Levels in supernatants of PC-3 cells. 
 
Time 
Point 
     Control 
(pg/ 105  
viable cell)   
Zoldronic  
Acid 1µM  
(pg/ 105 
 viable cell)   
ZA  
10µM  
  (pg/105) 
     ZA   
    60 µM 
   (pg/105) 
Z A 
 90µM  
(pg/ 105)   
ZA 
 100µM  
(pg/ 105 )   
24 hrs 10.10±0.84 
 
3.57±1.04 
 
2.31±0.40 
 
2.33±1.17 
 
1.93 ±1.08 3.45 ± 1.09 
48 hrs 20.01± 0.33 
 
11.12 ±0.31 
 
9.16±0.41 
 
10.44±0.61 10.72±1.53 8.9 ±0.94 
72 hrs 24.04±2.60 
 
10.99±0.62 
 
8.36±1.10 
 
8.16±0.80 7.76±0.41 7.24±0.85 
 
There was significant decrease in IL-6 secretion in the 1-100 M concentrations 
in PC-3 cells (Table 3.1.). The decrease in IL-6 levels in the presence of zoledronic acid 
concentrations comparing to control group was statistically significant (p< 0.05). 
However there was no significant difference between 1 µM and 100 µM zoledronic acid 
concentration except in 72 hours exposure. There was slide difference between 1 µM 
and 100 µM in 72 hours. 
IL-6 levels were decreased by various zoledronic acid concentrations (1, 10, 60, 
90, 100 µM) in time and dose dependent manner in PC-3 cell lines. The displayed data 
was average values from 24, 48 and 72 hr exposure time points (Figure 3.6.). 
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Figure 3.6.  Time and dose dependent decrease of IL-6 levels in the supernatants of 
PC-3 cells. (24, 48 and 72 hrs) 
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These data suggest that zoledronic acid inhibits the expression and secretion of 
IL-6 normally produced in high levels in PC-3 cell lines. These data imply that anti 
tumor effects of zoledronic acid could be also mediated by interfering IL-6 signaling 
pathways in prostate cells.  
 
3.2 Discussions 
 
In the literature the first data on cytotoxic effect of zoledronic acid was produced 
by Aparicio A et al in myeloma cell lines (Aparici et al, 1998). Then several studies 
(Lee et al, 2001, Witters et al, 2002; Fromigue et al, 2000; Mundy et al, 2001, Jagdev et 
al, 2000, Jagdev et al, 2001, Derenne et al, 1999, Tassone et al, 2000, Corey et al, 2003, 
Lee et al, 2002) have suggested direct antiproliferative and pro-apoptotic effects of the 
bisphosphonates on breast, prostate, and myeloma cancer cells.  
Lee et al studied the effects of pamidronate and zoledronic acid on prostate 
cancer cell growth in vitro. Three separate prostate cancer cell lines were seeded in 96-
well plates and incubated in serum-free media with or without the bisphosphonates at 
various concentrations for up to 72 hours. The numbers of cells remaining were 
determined indirectly by measuring the absorbance of crystal violet dye stain in viable 
cells. In all cell lines, treatment with 100-mol/L pamidronate induced significant cell 
death compared with untreated cells, whereas lower concentrations (25 and 50 mol/L) 
caused cell stasis. In contrast, zoledronic acid 100 mol/L did not cause cell death but 
caused cell cytostasis, even at concentrations as low as 10 mol/L. In the presence of 
serum, both bisphosphonates inhibited prostate cancer cell growth, but only zoledronic 
acid was effective at lower concentrations (25–50 mol/L). In a separate in vitro study 
of zoledronic acid with a cyclooxygenase inhibitor in the DU-145 human prostate 
carcinoma cell line (Witters et al, 2002) the effects on cell growth were determined 
using the 3,[4,5-dimethylthiazol-2-41]-2,5-diphenyltetrazolium bromide (MTT) dye 
assay. Cell exposure to zoledronic acid (1–10 mol/L) resulted in a dose-dependent 
growth inhibition (8%–70%). The combination gave an additive inhibitory effect on cell 
number compared with zoledronic acid treatment (Witters et al, 2002). Studies have also 
shown that the combination of zoledronic acid plus docetaxel resulted in additive 
apoptotic effects on PC–3 and DU–145 prostate cancer cells (Wei et al, 1989). 
 Two in vitro studies (Corey et al, 2003, Lee et al, 2002) have further examined 
the exposed 2 prostate cancer cell lines—LnCaP and PC-3—to zoledronic acid to 
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determine its effects on apoptosis and cell cycle progression. Compared with unexposed 
cells, the proportion of apoptotic cells among the PC-3 cells was increased after 1 day 
of treatment, but there was no significant difference among the LnCaP cells.The 
proliferation of PC-3 cells was inhibited by either continuous or pulsatile exposures of 
zoledronic acid in a dose-dependent manner (Tenta et al, 2004). Tenta et al also showed 
that zoledronic acid induces apoptosis in PC-3 prostate cancer cells (Tenta et al, 2005). 
In a recent study of the effects of several bisphosphonates on PC–3 prostate 
cancer cells, zoledronic acid markedly inhibited cell growth through a combination of 
cytostatic and apoptotic effects (Dumon et al, 2004). Notably, zoledronic acid was the 
most potent bisphosphonate, exerting profound antiproliferative effects more rapidly 
than either pamidronate or ibandronate.  
The known effects of zoledronic acid were confirmed in our experimental 
conditions. Our data also proved that the cytotoxic effect of zoledronic acid was dose- 
and time- dependent in PC-3 cell line as displayed in several studies (Figure 3.3.). We 
also tested the apoptotic effect of zoledronic acid on PC-3 cell lines by using two 
different apoptosis measurement assay. It was shown that zoledronic acid induces 
apoptosis and this effect was also time and dose dependent manner (Figure 3.4. and 
3.5.).  
In summary we found that zoledronic acid have two main effects on PC-3 cell 
lines. The cytotoxic and apoptotic effect of zoledronic acid was dependent on time and 
concentration. The second finding was that the expression of IL-6 was downregulated in 
time and dose dependent manner by zoledronic acid.  
IL-6 is produced by lymphoid, non-lymphoid cells, and cancer cells (Kishimoto 
et al, 1989). IL-6 is a multifunctional cytokine that plays an important role in the 
regulation of hematopoiesis, immune response, inflammation, bone metabolism, and 
neural development (Kishimoto et al, 1992). It has been demonstrated that normal 
prostate epithelial cells, cells derived from benign prostatic hyperplasia and primary 
prostate tumors secrete IL-6 in cell culture (Twillie et al, 1995). 
IL-6 can increase the proliferation of prostate cancer cells (McCarty et al, 2004) 
and treatment of cultures of androgen insensitive prostatic cancer cell lines PC-3 and 
DU145 with anti-IL-6 antibodies decreases growth rates of both cell lines (Borsellino et 
al, 1995). In contrast, androgen sensitive cell line LNCaP showed some divergence in 
reported effects of IL-6. Both stimulation and inhibition of proliferation being reported 
in this cell line (Okamoto et al, 1997; Levesque et al, 1998).  
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It was shown that bisphosphonates induce both myeloma cell and bone marrow 
stromal cells (BMSCs) apoptosis. Furthermore, at lower concentrations, they induce a 
significant inhibition (40% and 60%, respectively) of the constitutive production of 
interleukin-6 (IL-6) by BMSCs. In conclusion, the apoptosis of myeloma cells and 
BMSCs and the inhibition of IL-6 production induced by bisphosphonates, mainly 
zoledronate, could have antitumoral effects in patients with MM (Derenne et al, 1999). 
Interleukin-6 (IL-6) is the major growth and survival factor for multiple 
myeloma (MM), and has been shown to protect MM cells from apoptosis induced by a 
variety of agents (Tassone et al, 2002). IL-6 receptor antagonists, which prevent the 
assembly of functional IL-6 receptor complexes, inhibit cell proliferation and induce 
apoptosis in MM cells (Tassone et al, 2002). 
It was shown that the IL-6 receptor super-antagonist Sant7 might enhance the 
antiproliferative and apoptotic effects induced by the combination of dexamethasone 
and zoledronic acid on human multiple myeloma (MM) cell lines. Sant7 significantly 
enhanced growth inhibition and apoptosis induced by dexamethasone and zoledronic 
acid on both MM cell lines. These results indicate that overcoming IL-6 mediated cell 
resistance by Sant7 potentiates the effect of bisphosphonates on MM cell growth and 
survival, providing a rationale for therapies including IL-6 antagonists in MM. (Tassone 
et al, 2002). Furthermore, exogenous administration of interleukin 6 (IL-6) inhibited the 
doxorubicin-induced apoptosis of PC-3 cells (Tenta et al, 2004). 
 In vitro studies have demonstrated the antitumor potential of zoledronic acid on 
myeloma cell lines, but few data are available on its effects on bone marrow stromal 
cells (BMSCs). In vitro exposure to the lowest concentrations of zoledronic acid 
decreased IL-6 production by on bone marrow stromal cells (BMSCs) (Corso et al, 
2005).  
 In our study, we confirmed that zoledronic acid also inhibited the expression of 
IL-6 significantly in PC-3 prostate cell lines. There is no data on the decreasing of IL-6 
levels induced by zoledronic acid in PC-3 cell lines in current literature. In addition we 
also found that decreasing of IL-6 expression by various zoledronic acid concentrations 
was not dose dependent. The data on the 1 µM and 100 µM zoledronic acid 
concentrations caused the more or less the same amount of decrease in IL-6 level. This 
was so significant that the 1 µM which is also achieved serum level in prostate patients 
switch off IL-6 secretion in significant level. This might be directly inactivation of IL-6 
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nuclear transcription factor by zoledronic acid. This new data implies new hypothesis 
that zoledronic acid may exert its antitumor effects via interfering IL-6 expression.  
 We speculate the effects of zoledronic acid on PC-3 cell lines might be mediated 
by interfering IL-6 signaling pathways. IL-6 has different effects on prostate cancer cell 
lines. The bases of these differences can be originated from multistep and alternative 
signal flow pathways used by IL-6 in different cells. For instance, there are two forms 
(membrane bound and soluble) of IL-6 receptor regulated tightly. Signal transducer gp-
130 in membrane is common substrate for several growth factors. Therefore its 
activation is not only dependent on IL-6.  
Moreover activated gp130 either simultaneously or preferentially triggers three 
intracellular pathways by altering its intracellular domain. IL-6 signaling was mediated 
by JAK-STAT, ras-raf-MAPK and PI3K-Akt signaling. It is suggested that, one or two 
alternative pathways are preferentially more active in different cell lines. IL-6 is also 
capable of up and down regulation by autocrine or paracrine effect and feed-back (Klein 
et al, 1989, Miki et al, 1989, Yee et al, 1989, Okamoto et al, 1997, Chung et al, 1999). 
The expression of IL-6 is regulated by several transcription factors such as AP-1, 
NFKapaB, CREB and c/EBP. It is considered that intracellular signaling pathways of 
IL-6 also regulate these transcription factors. Therefore mentioned IL-6 signaling 
pathways might be affected by zoledronic acid. The possible interacting proteins with 
zoledronic acid might be either the structural or regulatory component of the following 
signaling pathways. These are Ras-Raf-MAPK cascade involving cell proliferation, 
tumor suppressor and apoptotic pathways, cell cycle proteins (cyclins), posttranslational 
mechanisms of intracellular signaling proteins. Moreover, there may be not only one 
substrate for zoledronic acid; it may have multiple interacting substrates within the cell.  
At present, it is not certain which pathways in the upstream or downstream signal flow 
are disrupted by zoledronic acid. However, it was shown that zoledronic acid interferes 
with isoprenylation of intracellular small G proteins such as ras (Caraglia et al, 2004) 
by inhibiting the farnesyl pyrophosphate (FPP) synthase enzyme (Rogers et al, 2000), 
which is required for producing FPP and subsequently geranylgeranyl pyrophosphate 
(GGPP). 
 It is also shown that zoledronic acid induced apoptosis by either caspase 3 or 
caspase 9 (Oades et al, 2003). Although the apoptotic effect of zoledronic acid was 
diminished by co-treating with a broad spectrum caspase inhibitor, Z-VAD-FMK 
(Coxon et al, 2004), it is not clear whether zoledronic acid binds to one of caspases.  
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On the other hand the apoptotic effect of zoledronic acid may not be the 
premature action of zoledronic acid, since it is possible that zoledronic acid first inhibits 
signal transduction in the upstream regulation of apoptotic switch mechanism. This 
possibility may explain the apoptotic effect and decrease of IL-6 in PC-3 cells which 
was shown in our study. The observed apoptosis in PC-3 cells and decreases in IL-6 
expression seem to be paralel events. But these two effects of zoledronic acid might be 
either independent or associated. However it is uncertain whether the apoptotic pathway 
was triggered by zoledronic acid mediated-decrease of IL-6 level. It is also unknown 
whether the decrease in IL-6 expression is caused by zoledronic acid induced apoptosis. 
There is also another hypothesis that if these two events are independently controlled in 
prostate cancer cells, then it might be interpreted that zoledronic acid can exert its effect 
by inhibiting IL-6 autocrine effect mechanism. Therefore, there is a need to carry out 
further studies in order to define the new zoledronic acid substrates mediating apoptotic 
effects.  
Moreover it is also not certain that apoptotic pathway in these cell lines and IL-6 
down regulation pathway are independently active or related each other. As displayed in 
several studies including our’s, zoledronic acid switch on apoptotic pathway, therefore 
one of the outcome of apoptosis might lead to decreasing in expression of IL-6. But it 
has to be investigated further. 
This study indicates that the molecular target of zoledronic acid is likely to be 
one of the molecules involving in IL-6 expression or signaling pathway. If it is true, it 
could be possible to develop new treatment strategies for prostate cancer. It suggests 
that the inhibition of IL-6 may be a useful adjunct to prostate cancer therapy regarding 
to in vitro studies. It could be speculated that a therapeutic intervention that interferes 
with IL-6 signaling may be justified both at early and late stages of prostate 
carcinogenesis and could decrease morbidity in patients with advanced disease. On the 
other hand, the importance of IL-6 for androgen independent growth of tumor cells 
makes it a good candidate for targeted therapy in human carcinoma of the prostate.  
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CHAPTER 5 
 
CONCLUSIONS 
 
Zoledronic acid is a potent, nitrogen-containing bisphosphonate that inhibits 
bone resorption by reducing osteoclast proliferation and inducing osteoclast apoptosis. 
Zoledronic acid exerts direct antitumor effects by inducing apoptosis, inhibiting cell 
adhesion molecules, preventing prostate and breast cancer cell adherence to bone, 
reducing IL-6 secretion from myeloma stromal cells, and affecting angiogenesis. 
However, zoledronic acid’s mechanism of action is not clearly understood. Also, its 
molecular substrates in PC-3 cell lines are not known. 
In this study we have showed that zoledronic acid reduces IL-6 expression in 
significant level in prostate cancer cell line PC-3. The ability of IL-6 to activate 
signaling through several distinct pathways may exert differential effects on various cell 
lines. IL-6 is using three intracellular pathways to transducing IL-6 signaling by binding 
gp130 then activating signal transducer and activator of transcription (STAT)-3, 
mitogen activated protein kinases (MAPK), and phosphatidylinositol 3-kinase (PI3K) 
signaling pathways, each depends upon different regions of gp130. 
Additional research is required to elucidate further the action of IL-6 and its role 
in the pathogenesis of advanced prostate cancer at the cellular and molecular levels. At 
present, it is not certain which pathways in the upstream or downstream signal flow are 
disrupted by zoledronic acid. New therapeutic strategies using anti-IL-6 monoclonal 
antibodies seem warranted in such patients for which conventional treatment holds little 
and may afford improved quality of life and survival benefit. 
These original data on the decreasing of IL-6 secretion by zoledronic acid in PC-
3 cells suggest that targeting IL-6 in future may have multiple benefits in prostate 
cancer patients in terms of developing alternative combined threapies in hormone 
refractory prostate cancer patients. 
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